Zymeworks (ZYME)
Develops antibody medicines and earns royalties from partner-run therapies.
Something off on this page? Send us feedback.
Develops antibody-based medicines and manages licensed assets, earning milestones and royalties as partners advance and commercialize programs such as Ziihera and pasritamig. Internal work focuses on ZW191 and ZW251 antibody-drug conjugates, while major partners control late-stage development and commercial execution.
Develops multifunctional antibody medicines while managing licensed assets that can generate milestones and royalties. Ziihera, a HER2-targeted bispecific antibody created with the Azymetric platform, is commercialized by Jazz Pharmaceuticals and BeOne Medicines in separate territories; pasritamig is a partner-run prostate-cancer program. Wholly owned work centers on ZW191 and ZW251 antibody-drug conjugates, with multispecific programs extending into oncology, inflammation, and autoimmune disease.
Combines protein engineering and drug chemistry to design bispecific antibodies, multispecific T-cell engagers, and antibody-drug conjugates. Partnerships shift later-stage development, commercialization, and manufacturing to larger drugmakers, while internal teams retain early research and selected clinical development. Revenue therefore depends on partner-controlled product sales, milestones, clinical progress, and regulatory decisions. The proposed Theravance Biopharma acquisition remains subject to closing conditions.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 17, 2026 | Wolfe Research | Initiate | Rating: — | |
| Aug 26, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $51 | Target: $55 |
| Aug 26, 2026 | Deutsche Bank | Target | Target: — | Target: $32 |
| Aug 7, 2026 | Truist Financial | Target | Target: $31 | Target: $32 |
| Aug 7, 2026 | Stifel Nicolaus | Target | Target: $40 | Target: $46 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $270.7M · Total debt $268.6M · Total assets $397.0M · Shareholders' equity $80.4M
- Revenue
- $4.6M
- Operating income
- −$42.2M
- Net income
- −$45.0M
No dividends on record.
| Institutions | 96.56% | 68.52M shares | |
|---|---|---|---|
| 208 holders · as of Jun 30, 2026 | |||
| Insiders | 23.46% | 16.65M shares | |
| 7 holders · as of Jul 6, 2026 | |||
| Adds to | 120.02% | ||
70.96M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 120.02%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
EcoR1 Capital, LLCInstitution | 32.37% | 22.97M | as of Jun 30, 2026 |
Oleg NodelmanInsiderdirector, 10 percent owner | 22.15% | 15.72M | filed Feb 18, 2025 |
Rubric Capital Management LPInstitution | 9.86% | 7.00M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 5.99% | 4.25M | as of Jun 30, 2026 |
Perceptive Advisors LLCInstitution | 5.89% | 4.18M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 12, 2026 | Mark Hollywood | officer: EVP & Chief Operating Officer | −6,120 | $22.67 |
| Jan 12, 2026 | Kenneth Galbraith | director, officer: Chair & CEO | −30,424 | $22.67 |
| Jan 12, 2026 | Paul Andrew Moore | officer: Chief Scientific Officer | −9,560 | $22.67 |
| Jan 12, 2026 | Jeffrey T. L. Smith | officer: EVP & Chief Medical Officer | −9,310 | $22.67 |
| Jan 5, 2026 | Paul Andrew Moore | officer: Chief Scientific Officer | −20,110 | $25.10 |
- AstraZeneca (ADR)
HER2-ADC leader; Enhertu dominates 2L gastric and HER2+ breast globally.
- Pfizer
Global pharma with HER2 inhibitor Tukysa and trastuzumab biosimilar Trazimera
- Xencor
XmAb Fc-engineering platform licensed broadly; no HER2 oncology overlap.
- MacroGenics
DART/TRIDENT bispecific platform licensor and oncology ADC developer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Zymeworks | $27.31 | +1.85% | $1.97B | — | 9.4 | 53.1 | −90.6% |
| AstraZeneca (ADR) | $168.91 | +0.48% | $260.70B | 25.2 | 15.9 | 4.2 | +6.4% |
| Pfizer | $27.97 | +0.83% | $158.10B | 36.7 | 10.0 | 2.5 | +2.6% |
| Xencor | $25.23 | +0.78% | $1.86B | — | — | 17.7 | +17.5% |
| MacroGenics | $4.13 | +0.21% | $261.9M | — | — | 1.6 | +47.6% |
| Median | 30.9 | 12.9 | 3.4 | +11.9% |